TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
D: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
B: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Placeo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: St. John's Wort-900 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-900 mg/day | Arm Label: St. John's Wort-1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-1800mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placeo | Intervention Type: DRUG; Name: St. John's Wort-900 mg/day; Assigned to Arm(s): St. John's Wort-900 mg/day | Intervention Type: DRUG; Name: St. John's Wort-1800mg/day; Assigned to Arm(s): St. John's Wort-1800 mg/day
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation
Brief Summary: To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1
B: Arm Label: Arm 1 (ceralasertib+olaparib); Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Ceralasertib | Arm Label: Arm 2 (olaparib monotherapy); Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Arm 3 (placebo); Type: EXPERIMENTAL; Interventions: Drug: Placebo to match olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib), Arm 2 (olaparib monotherapy) | Intervention Type: DRUG; Name: Ceralasertib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib) | Intervention Type: DRUG; Name: Placebo to match olaparib; Assigned to Arm(s): Arm 3 (placebo)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
D: Arm Label: KU-0059436 (AZD2281) 100 mg BID; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Arm Label: KU-0059436 (AZD2281) 400 mg BID; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436 (AZD2281) 100 mg BID | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436 (AZD2281) 400 mg BID

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of the Efficiency of a Treatment by Bumetanide in a Population of Autistic Children
Brief Summary: The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism


Options:
A: Arm Label: Bumetanide; Type: EXPERIMENTAL; Interventions: Drug: bumetanide | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: bumetanide | Intervention Type: DRUG; Name: bumetanide; Assigned to Arm(s): Bumetanide, Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone
D: Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV, Unicenter, Randomized, Double-Blind, Parallel-Group, Comparaty Study of Intravenous and Oral Iron vs Placebo in Patient Under Extracorporeal Circulation in Cardiovascular Surgery
Brief Summary: Anaemia is a common postoperative problem of cardiovascular surgery after cardiopulmonary bypass (CPB). Because of this the need for hemoderived blood transfusions is high. The purpose of this study was to compare the clinical efficacy of intravenous and oral iron in anaemia and the impact of the iron on the transfusion rate in postoperative cardiovascular surgery under extracorporeal circulation.


Options:
A: Arm Label: Ferric Carboxymaltose (FCM); Type: EXPERIMENTAL; Interventions: Drug: Ferric Carboxymaltose (FCM) | Arm Label: Ferrous Sulfate tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ferrous Sulfate tablets | Intervention Type: DRUG; Name: Ferric Carboxymaltose (FCM); Assigned to Arm(s): Ferric Carboxymaltose (FCM) | Intervention Type: DRUG; Name: Ferrous Sulfate tablets; Assigned to Arm(s): Ferrous Sulfate tablets
B: Arm Label: Ferinject; Type: EXPERIMENTAL; Interventions: Drug: Ferinject | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ferinject | Intervention Type: DRUG; Name: Ferinject; Assigned to Arm(s): Ferinject, Placebo
C: Intervention Type: DRUG; Name: Venofer (intravenous iron sucrose); Assigned to Arm(s): N/A
D: Arm Label: IV trivalent saccharose hydroxide ferrous; Type: EXPERIMENTAL; Interventions: Drug: IV trivalent saccharose hydroxide ferrous | Arm Label: Oral ferrous fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ferrous fumarate | Arm Label: Oral and intravenous Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral and intravenous Placebo | Intervention Type: DRUG; Name: IV trivalent saccharose hydroxide ferrous; Assigned to Arm(s): IV trivalent saccharose hydroxide ferrous | Intervention Type: DRUG; Name: Oral ferrous fumarate; Assigned to Arm(s): Oral ferrous fumarate | Intervention Type: DRUG; Name: Oral and intravenous Placebo; Assigned to Arm(s): Oral and intravenous Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV, Unicenter, Randomized, Double-Blind, Parallel-Group, Comparaty Study of Intravenous and Oral Iron vs Placebo in Patient Under Extracorporeal Circulation in Cardiovascular Surgery
Brief Summary: Anaemia is a common postoperative problem of cardiovascular surgery after cardiopulmonary bypass (CPB). Because of this the need for hemoderived blood transfusions is high. The purpose of this study was to compare the clinical efficacy of intravenous and oral iron in anaemia and the impact of the iron on the transfusion rate in postoperative cardiovascular surgery under extracorporeal circulation.


Options:
A: Intervention Type: DRUG; Name: Venofer (intravenous iron sucrose); Assigned to Arm(s): N/A
B: Arm Label: IV trivalent saccharose hydroxide ferrous; Type: EXPERIMENTAL; Interventions: Drug: IV trivalent saccharose hydroxide ferrous | Arm Label: Oral ferrous fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ferrous fumarate | Arm Label: Oral and intravenous Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral and intravenous Placebo | Intervention Type: DRUG; Name: IV trivalent saccharose hydroxide ferrous; Assigned to Arm(s): IV trivalent saccharose hydroxide ferrous | Intervention Type: DRUG; Name: Oral ferrous fumarate; Assigned to Arm(s): Oral ferrous fumarate | Intervention Type: DRUG; Name: Oral and intravenous Placebo; Assigned to Arm(s): Oral and intravenous Placebo
C: Arm Label: Ferric carboxymaltose; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Normal saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): Ferric carboxymaltose | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Ferric carboxymaltose, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ferinject ® (Ferric carboxymaltose) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9%) | Intervention Type: DRUG; Name: Ferinject ® (Ferric carboxymaltose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal saline (0.9%); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Memantine in Adult Autism Spectrum Disorder
Brief Summary: The purpose of this study is to see if memantine is helpful in managing problematic symptoms in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder not otherwise specified (NOS).


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effect of Cranberry Capsules on the Occurrence of Urinary Tract Infections During Post-acute Rehabilitation of Spinal Cord Injured Patients
Brief Summary: The purpose of this study is to establish whether cranberry capsules reduce rates of urinary tract infections during initial rehabilitation immediately after spinal cord injury.


Options:
A: Arm Label: Cranberry-lingonberry juice; Type: EXPERIMENTAL; Interventions: Other: Cranberry-lingonberry juice | Arm Label: Placebo juice; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo juice | Intervention Type: OTHER; Name: Cranberry-lingonberry juice; Assigned to Arm(s): Cranberry-lingonberry juice | Intervention Type: OTHER; Name: Placebo juice; Assigned to Arm(s): Placebo juice
B: Arm Label: Cranberry powder capsules; Type: EXPERIMENTAL; Interventions: Drug: Cranberry powder capsules | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo powder capsules | Intervention Type: DRUG; Name: Cranberry powder capsules; Assigned to Arm(s): Cranberry powder capsules | Intervention Type: DRUG; Name: Placebo powder capsules; Assigned to Arm(s): Placebo capsules
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: WelTract | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: WelTract; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Control
D: Arm Label: Cranberry capsule; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cranberry capsules | Arm Label: Placebo capsule; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry capsules; Assigned to Arm(s): Cranberry capsule, Placebo capsule

Answer: D